Hagström Hannes, Adams Leon A, Allen Alina M, Byrne Christopher D, Chang Yoosoo, Duseja Ajay, Grønbæk Henning, Ismail Mona H, Jepsen Peter, Kanwal Fasiha, Kramer Jennifer, Loomba Rohit, Mark Henry E, Newsome Philip N, Rinella Mary E, Rowe Ian A, Ryu Seungho, Sanyal Arun, Schattenberg Jörn M, Serper Marina, Sheron Nick, Simon Tracey G, Spearman C Wendy, Tapper Elliot B, Villota-Rivas Marcela, Wild Sarah H, Wong Vincent Wai-Sun, Yilmaz Yusuf, Zelber-Sagi Shira, Åberg Fredrik, Lazarus Jeffrey V
Department of Upper GI, Division of Hepatology, Karolinska University Hospital, Stockholm, Sweden.
Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden.
Hepatol Commun. 2024 Feb 3;8(2). doi: 10.1097/HC9.0000000000000386. eCollection 2024 Feb 1.
Following the adoption of new nomenclature for steatotic liver disease, we aimed to build consensus on the use of International Classification of Diseases codes and recommendations for future research and advocacy.
Through a two-stage Delphi process, a core group (n = 20) reviewed draft statements and recommendations (n = 6), indicating levels of agreement. Following revisions, this process was repeated with a large expert panel (n = 243) from 73 countries.
Consensus ranged from 88.8% to 96.9% (mean = 92.3%).
This global consensus statement provides guidance on harmonizing the International Classification of Diseases coding for steatotic liver disease and future directions to advance the field.
在采用脂肪性肝病新命名法之后，我们旨在就国际疾病分类编码的使用以及未来研究与宣传建议达成共识。
通过两阶段德尔菲法，一个核心小组（n = 20）审查了声明草案和建议（n = 6），表明了一致程度。修订后，对来自73个国家的大型专家小组（n = 243）重复了这一过程。
共识率在88.8%至96.9%之间（平均 = 92.3%）。
这一全球共识声明为统一脂肪性肝病的国际疾病分类编码以及推动该领域发展的未来方向提供了指导。
Zotero 插件